Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from NLS Pharmaceutics ( (NLSP) ).
On June 5, 2025, NLS Pharmaceutics Ltd. entered into a fourth amendment to its merger agreement with Kadimastem Ltd. and NLS Pharmaceutics (Israel) Ltd. This amendment clarifies the exchange ratio for shares and outlines adjustments related to closing cash and indebtedness. It also specifies conditions for the potential sale of legacy assets and the election of Kadimastem board members to NLS Pharmaceutics’ board. The parties are committed to completing the merger diligently, which could impact the company’s market positioning and shareholder structure.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a Swiss-based company operating in the pharmaceutical industry. It focuses on developing treatments for rare and complex central nervous system disorders, aiming to address unmet medical needs.
Average Trading Volume: 168,330
Technical Sentiment Signal: Sell
Current Market Cap: $6.84M
See more insights into NLSP stock on TipRanks’ Stock Analysis page.